$740 Million is the total value of Foresite Capital Management IV, LLC's 13 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma Inc. | $225,156,000 | -25.3% | 9,671,643 | 0.0% | 30.44% | -15.7% | |
| LYEL | New | Lyell Immunopharma, Inc. | $215,703,000 | – | 13,282,181 | +100.0% | 29.16% | – |
| PHVS | Pharvaris N.V. | $60,770,000 | -33.4% | 3,261,926 | 0.0% | 8.21% | -24.9% | |
| ACRS | Aclaris Therapeutics, Inc. | $59,687,000 | -30.3% | 3,399,034 | 0.0% | 8.07% | -21.4% | |
| QSI | New | Quantum-Si Incorporated | $54,724,000 | – | 4,463,619 | +100.0% | 7.40% | – |
| KURA | Kura Oncology, Inc. | $38,571,000 | -26.2% | 1,849,947 | 0.0% | 5.21% | -16.8% | |
| NRIX | Sell | Nurix Therapeutics, Inc. | $31,990,000 | -16.9% | 1,205,798 | -2.6% | 4.32% | -6.2% |
| RLAY | Sell | Relay Therapeutics, Inc. | $20,358,000 | -72.5% | 556,380 | -74.0% | 2.75% | -68.9% |
| CYTK | Sell | Cytokinetics Incorporated | $10,788,000 | -47.4% | 545,101 | -38.2% | 1.46% | -40.7% |
| OLMA | Sell | Olema Pharmaceuticals, Inc. | $9,570,000 | -26.6% | 342,030 | -13.0% | 1.29% | -17.2% |
| CBAY | Cymabay Therapeutics, Inc. | $7,792,000 | -4.0% | 1,787,094 | 0.0% | 1.05% | +8.3% | |
| DBTX | Decibel Therapeutics, Inc. | $2,560,000 | -24.3% | 297,711 | 0.0% | 0.35% | -14.6% | |
| TPST | New | Tempest Therapeutics, Inc. | $2,127,000 | – | 190,212 | +100.0% | 0.29% | – |
| RACA | Exit | Therapeutics Acquisition Corp | $0 | – | -350,000 | -100.0% | -0.44% | – |
| ALXO | Exit | ALX Oncology Holdings Inc. | $0 | – | -785,945 | -100.0% | -6.94% | – |
| KROS | Exit | Keros Therapeutics, Inc. | $0 | – | -1,382,641 | -100.0% | -10.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.